Document:

FORBEARANCE
AND FIFTH AMENDMENT TO

AMENDED
AND RESTATED LOAN AND SECURITY agreement

 

This
Forbearance and Fifth Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered
into this 16th day of January, 2019 by and among (a) SILICON VALLEY BANK, a California corporation (“Bank”),
and (b) (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”), (ii) GENTRIS, LLC, a Delaware
limited liability company (“Delaware Subsidiary”), (iii) VIVOPHARM, LLC, a Delaware limited liability
company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD, a company incorporated under the laws of
Australia (“Australian Borrower”, and together with Parent, Delaware Subsidiary, and Vivo, jointly and severally,
individually and collectively, “Borrower”).

 

Recitals

 

A.
Bank and Borrower have entered into that certain Amended and Restated Loan and Security Agreement dated as of March 22, 2017,
as amended by that certain Waiver and First Amendment to Amended and Restated Loan and Security Agreement dated as of May 14,
2018, between Borrower and Bank, as further amended by that certain Joinder and Second Amendment to Amended and Restated Loan
and Security Agreement dated as of June 21, 2018, between Borrower and Bank (the “Second Amendment”), as further
amended by that certain Waiver and Third Amendment to Amended and Restated Loan and Security Agreement dated as of August 20,
2018 between Borrower and Bank, and as further amended by that certain Waiver and Fourth Amendment to Amended and Restated Loan
and Security Agreement dated as of November 19, 2018 (the “Fourth Amendment”) between Borrower and Bank (as
the same may from time to time be further amended, modified, supplemented or restated, the “Loan Agreement”).

 

B.
Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.

 

C.
Borrower has requested that Bank amend the Loan Agreement to (i) forbear on the Stated Defaults (as defined herein) and (ii)
make certain other revisions to the Loan Agreement as more fully set forth herein.

 

D.
In reliance upon the representations and warranties set forth below, Bank has agreed to so amend certain provisions of the
Loan Agreement, but only to the extent provided in this Amendment, and only in accordance with the terms and subject to the conditions
set forth below.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing
recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to
be legally bound, the parties hereto agree as follows:

 

1.
Definitions.
Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

 

    	 

    	 

    

 

2.
Amendments to Loan Agreement.

 

2.1
Section 2.4(a) (Interest Rate). Section 2.4(a) is amended by deleting the words “one and one-half of one percent (1.50%)”
appearing therein and inserting in lieu thereof “two and one-quarter of one percent (2.25%)”.

 

2.2
Section 6.2(m) (Financial Statements, Reports, Certificates). Section 6.2 is hereby amended by (i) deleting ; and” in
subsection (k) and replacing it with “;”, (ii) deleting “.” in subsection (l) and replacing it with “;
and”, and (iii) inserting the following to appear as subsection (m) thereto:

 

“
(m) commencing on the first Monday following the Fifth Amendment Effective Date and continuing every Monday of each calendar week
thereafter, by 5:00 PM (Boston, Massachusetts time) of each such Monday, weekly cash flow projections for at least the immediately
succeeding fourteen (14) week period that includes all expenses and foreseeable expenses, in a form and substance acceptable to
Bank in all respects.”

 

2.3
Section 6 (Affirmative Covenants). The Loan Agreement is amended by inserting the following new provisions to appear as Sections
6.19, 6.20 and 6.21 thereof:

 

“
6.19 2019 Term Sheet Event. On or before February 15, 2019, provide Bank with evidence in a form and substance acceptable
to Bank in all respects that the 2019 Term Sheet Event has occurred.

 

6.20
Confirmation Event. On or before February 28, 2019, provide Bank with evidence in a form and substance acceptable to Bank
in all respects that the Confirmation Event has occurred.

 

6.21
Closing Event. On or before April 15, 2019, provide Bank with evidence in a form and substance acceptable to Bank in all respects
that the Closing Event has occurred.”

 

2.4
Section 13 (Definitions). The following term and its definitions set forth in Section 13.1 is amended in its entirety and
replaced with the following:

 

“
“Revolving Line Maturity Date” is April 15, 2019.”

 

2.5
Section 13 (Definitions). The Loan Agreement shall be amended by inserting the following new definitions to appear alphabetically
in Section 13.1 thereof:

 

“
“2019 Term Sheet Event” means written confirmation by Bank that it has received evidence satisfactory to Bank
in its sole discretion that Borrower has received, after the Fifth Amendment Effective Date, but on or prior to February 15, 2019,
either a signed letter of intent or signed bona fide term sheet for the sale of all or substantially all of Borrower’s equity
securities or assets to buyers satisfactory to Bank in all respects with an anticipated closing date of on or before April 15,
2019 (the “Term Sheet”).”

 

    	2

    	 

    

 

“
“Closing Event” means written confirmation by Bank that it has received evidence satisfactory to Bank in its
sole discretion, after the Fifth Amendment Effective Date, but on or prior to April 15, 2019, that the transaction described in
the Term Sheet has closed.”

 

“
“Confirmation Event” means written confirmation by Bank that it has received evidence satisfactory to Bank
in its sole discretion that, after the Fifth Amendment Effective Date, but on or prior to February 28, 2019, the buyers outlined
in the Term Sheet have provided written confirmation that such buyers and Borrower have agreed to proceed with the transaction
described in the Term Sheet and that any due diligence required by such buyers with respect to the Term Sheet has begun.”

 

“
“Fifth Amendment Effective Date” means January 16, 2019.”

 

“
“Term Sheet” is defined in the definition of 2019 Term Sheet Event.”

 

3.
Limitation of Amendments.

 

3.1
The amendments set forth in Section 2 above are effective for the purposes set forth herein and shall be limited precisely
as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition
of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or
in connection with any Loan Document.

 

3.2
This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed
and shall remain in full force and effect.

 

4.
Forbearance Fee.
In consideration of Bank’s forbearance with respect to the Stated Defaults (as defined below), and in addition to all other
fees due under the Loan Documents, Borrower shall pay to Bank a forbearance fee equal to Fifty Thousand Dollars ($50,000.00) (the
“Forbearance Fee”), which Forbearance Fee shall be (a) fully earned as of the Fifth Amendment Effective Date,
(b) secured by the Collateral, and (c) constitute a portion of the Obligations. The Forbearance Fee and, notwithstanding anything
to the contrary contained in the Fourth Amendment, (x) the Twenty Five Thousand Dollar ($25,000.00) Waiver Fee (as defined in
the Fourth Amendment) and (y) the Twenty Five Thousand Dollar ($25,000.00) waiver fee described in Section 12(b)(i) of the Fourth
Amendment, shall each be due and payable upon the earlier of (i) the occurrence of an Event of Default (other than the Stated
Defaults), (ii) the repayment in full of the Revolving Line, (iii) the acceleration of the Revolving Line, or (iv) April 15, 2019.

 

    	3

    	 

    

 

5.
Discretionary Advances.
Notwithstanding anything to the contrary contained in Section 2.2(a) of the Loan Agreement or otherwise contained in the Loan
Agreement or the other Loan Documents, Borrower hereby confirms, acknowledges and agrees, that in consideration for Bank’s
agreements hereunder, Bank shall have no obligation to make any Advances pursuant to Section 2.2(a) of the Loan Agreement, and
any Advances made under Section 2.2(a) shall be made on a case by case basis in Bank’s sole and absolute discretion. In
addition to the foregoing, Borrower hereby confirms, acknowledges and agrees, that in consideration for Bank’s agreements
hereunder, from and after the date of this Amendment, (a) the outstanding balance of Advances made under the Revolving Line shall
not exceed Three Million Dollars ($3,000,000.00) in the aggregate at any time, and (b) Bank shall have no obligation to make,
and Borrower shall have no right to request, any Advance if after giving effect to such Advance the aggregate balance of Advances
made under the Revolving Line would exceed Three Million Dollars ($3,000,000.00).

 

6.
Acknowledgement of Default; Forbearance
by Bank. Borrower acknowledges that it is (a) currently in default
under the Loan Agreement by (i) its failure to comply with the Additional Capital Event set forth in Section 6.18 thereof as of
November 30, 2018 and (ii) its default under Section 8.12 thereof as a result of the occurrence of an Event of Default under and
as defined in the PFG Loan Agreement (collectively, the “Existing Defaults”) and (b) anticipated to be in default
under the Loan Agreement by its failure to comply with the following covenants: (i) the Adjusted EBITDA covenant set forth in
Section 6.9(a) thereof as of the months ending December 31, 2018, January 31, 2019, February 28, 2019, and March 31, 2019, (ii)
the Minimum Revenue covenant contained in Section 6.9(b) thereof for the quarter ending December 31, 2018, and (iii) the minimum
Liquidity covenant sent forth in Section 6.9(c) thereof as of the months ending December 31, 2018, January 31, 2019, February
28, 2019, and March 31, 2019 (collectively, the “Anticipated Defaults”, and together with the Existing Defaults,
collectively, the “Stated Defaults”). Bank, however, hereby agrees to forbear from exercising its rights and
remedies with respect to the Stated Defaults until the earlier to occur of (i) an Event of Default under the Loan Agreement (other
than the failure of Borrower to comply with the above covenants) or (ii) February 15, 2019 (the “Forbearance End Date”);
provided, however, that upon the occurrence of the 2019 Term Sheet Event, the Forbearance End Date shall be February 28, 2019;
provided, further, that upon the occurrence of the Confirmation Event, the Forbearance End Date shall be April 15, 2019. Borrower
hereby acknowledges and agrees that except as specifically provided herein, nothing in this Section or anywhere in this Amendment
shall be deemed or otherwise construed as a waiver by Bank of any of its rights and remedies pursuant to the Loan Documents, applicable
law or otherwise.

 

7.
Deferred Revenue.
Borrower acknowledges that notwithstanding any other provision of the Loan Agreement, commencing on the Fifth Amendment Effective
Date and continuing until the earlier of (a) the Forbearance End Date, and (b) April 15, 2019, Eligible Accounts shall include
Accounts owing from an Account Debtor with respect to which Borrower has received Deferred Revenue (but only to the extent of
such Deferred Revenue), except for Deferred Revenue related to upfront storage fees.

 

8.
Representations and Warranties.
To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to Bank as follows:

 

8.1
Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are
true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred
and is continuing;

 

    	4

    	 

    

 

8.2
Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement,
as amended by this Amendment;

 

8.3
The organizational documents of (i) Parent and Delaware Subsidiary delivered to Bank on the Effective Date and (ii) Vivo and
Australian Borrower delivered to Bank on the 2018 Amendment Date remain true, accurate and complete and have not been amended,
supplemented or restated and are and continue to be in full force and effect;

 

8.4
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, have been duly authorized;

 

8.5
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower,
(b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental
or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

 

8.6
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof,
binding on Borrower, except as already has been obtained or made; and

 

8.7
This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’
rights.

 

9.
Ratification of Intellectual Property
Security Agreements. Parent hereby ratifies, confirms and reaffirms,
all and singular, the terms and conditions of a certain Intellectual Property Security Agreement dated as of March 22, 2017 between
Parent and Bank, as amended by that certain First Amendment to Intellectual Property Security Agreement dated as of June 16, 2017
(as amended, the “Parent IP Security Agreement”), and acknowledges, confirms and agrees that the Parent IP
Security Agreement (a) contains an accurate and complete listing of all Intellectual Property Collateral, as defined in the Parent
IP Security Agreement, and (b) shall remain in full force and effect. Delaware Subsidiary hereby ratifies, confirms and reaffirms,
all and singular, the terms and conditions of a certain Intellectual Property Security Agreement dated as of June 16, 2017 between
Delaware Subsidiary and Bank (the “Delaware Subsidiary IP Security Agreement”), and acknowledges, confirms
and agrees that the Delaware Subsidiary IP Security Agreement (a) contains an accurate and complete listing of all Intellectual
Property Collateral, as defined in the Delaware Subsidiary IP Security Agreement, and (b) shall remain in full force and effect.
Vivo hereby ratifies, confirms and reaffirms, all and singular, the terms and conditions of a certain Intellectual Property Security
Agreement dated as of June 21, 2018 between Vivo and Bank (the “Vivo IP Security Agreement”), and acknowledges,
confirms and agrees that the Vivo IP Security Agreement (a) contains an accurate and complete listing of all Intellectual Property
Collateral, as defined in the Vivo IP Security Agreement, and (b) shall remain in full force and effect. Australian Borrower hereby
ratifies, confirms and reaffirms, all and singular, the terms and conditions of a certain Intellectual Property Security Agreement
dated as of June 21, 2018 between Australian Borrower and Bank (the “Australian Borrower IP Security Agreement”),
and acknowledges, confirms and agrees that the Australian Borrower IP Security Agreement (a) contains an accurate and complete
listing of all Intellectual Property Collateral, as defined in the Australian Borrower IP Security Agreement, and (b) shall remain
in full force and effect.

 

    	5

    	 

    

 

10.
Ratification of Perfection Certificates.
Parent hereby ratifies, confirms and reaffirms, all and singular, the terms and disclosures contained in the Perfection Certificate
dated as of March 22, 2017, as amended in connection with the Second Amendment, delivered by Parent to Bank (the “Parent
Perfection Certificate”), and acknowledges, confirms and agrees the disclosures and information Parent provided to Bank
in said Parent Perfection Certificate have not changed, as of the date hereof. Delaware Subsidiary hereby ratifies, confirms and
reaffirms, all and singular, the terms and disclosures contained in the Perfection Certificate dated as of March 22, 2017, as
amended in connection with the Second Amendment, delivered by Delaware Subsidiary to Bank (the “Delaware Subsidiary Perfection
Certificate”), and acknowledges, confirms and agrees the disclosures and information Delaware Subsidiary provided to
Bank in said Delaware Subsidiary Perfection Certificate have not changed, as of the date hereof. Vivo hereby ratifies, confirms
and reaffirms, all and singular, the terms and disclosures contained in the Perfection Certificate dated as of June 21, 2018,
delivered by Vivo to Bank (the “Vivo Perfection Certificate”), and acknowledges, confirms and agrees the disclosures
and information Vivo provided to Bank in said Vivo Perfection Certificate have not changed, as of the date hereof. Australian
Borrower hereby ratifies, confirms and reaffirms, all and singular, the terms and disclosures contained in the Perfection Certificate
dated as of June 21, 2018, delivered by Australian Borrower to Bank (the “Australian Borrower Perfection Certificate”),
and acknowledges, confirms and agrees the disclosures and information Australian Borrower provided to Bank in said Australian
Borrower Perfection Certificate have not changed, as of the date hereof.

 

11.
No Defenses of Borrower. In
consideration of the foregoing, Borrower hereby acknowledges and agrees that it has no offsets, defenses, causes of action, suits,
damages, claims, or counterclaims against Bank, SVB Financial Group, or any of their respective officers, directors, employees,
attorneys, representatives, predecessors, successors, and assigns (collectively, the “Bank Released Parties”)
with respect to the Obligations, the Loan Documents, the Collateral, any Bank Services Agreement, any contracts, promises, commitments,
or other agreements to provide, to arrange for, or to obtain loans or other financial accommodations to or for Borrower, or otherwise,
and that if Borrower now has, or ever did have, any offsets, defenses, causes of action, suits, damages, claims, or counterclaims
against one or more of the Bank Released Parties, at law or in equity, whether known or unknown, from the beginning of the world
through this date and through the time of execution of this Waiver (collectively, the “Released Claims”) all
of them are hereby expressly WAIVED and Borrower hereby RELEASES the Bank Released Parties from any liability therefor. Borrower
hereby irrevocably agrees to refrain from directly or indirectly asserting any claim or demand or commencing (or causing to be
commenced) any suit, action, arbitration or proceeding of any kind, in any court or before any tribunal or arbiter or arbitration
panel, against any Bank Released Party as to any of the Released Claims.

 

    	6

    	 

    

 

12.
Integration.
This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations
or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the
subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

 

13.
Counterparts.
This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute
one and the same instrument.

 

14.
Effectiveness.
This Amendment shall be deemed effective upon (a) the due execution and delivery to Bank of this Amendment by each party hereto,
(b) Borrower’s payment to Bank of Bank’s legal fees and expenses incurred in connection with this Amendment, and (c)
Bank’s receipt of the Acknowledgement of Amendment and Reaffirmation of Guaranty substantially in the form attached hereto
as Schedule 1, duly executed by the Guarantor.

 

[Signature
page follows.]

 

    	7

    	 

    

 

In
Witness Whereof, this Amendment and all documents
executed in connection therewith, or relating thereto, have been negotiated, prepared and deemed to be executed by Borrower in
the United States of America. In addition, the parties hereto have caused this Amendment to be duly executed and delivered as
of the date first written above.

 

	BANK	 
	 	 	 
	SILICON
    VALLEY BANK	 
	 	 	 
	By:	/s/
    John Lapides	 
	Name:	John
    Lapides	 
	Title:	Vice
    President	 

 

	BORROWER	 
	 	 	 
	CANCER
    GENETICS, INC.	 
	 	 	 
	By:	/s/
    John A. Roberts	 
	Name:	John
    A. Roberts	 
	Title:	Chief
    Executive Officer	 

 

	GENTRIS, LLC	 
	 	 	 
	By:	/s/
    John A. Roberts	 
	Name:	John
    A. Roberts	 
	Title:	Chief
    Executive Officer	 

 

	VIVOPHARM, LLC	 
	 	 	 
	By:	/s/
    John A. Roberts	 
	Name:	John
    A. Roberts	 
	Title:	Chief
    Executive Officer	 

 

[Signature
page to Forbearance and Fifth Amendment to

Amended
and Restated Loan and Security Agreement]

 

    	 

    	 

    

 

	Executed
    by RDDT A VIVOPHARM COMPANY PTY LTD in accordance with Section 127 of the Corporations Act 2001	 	 
	 	 	 
	/s/
    John A. Roberts	 	/s/
    Ralf Brandt
	Signature
    of director	 	Signature
    of director
	 	 	 
	John
    A. Roberts	 	Ralf
    Brandt
	Name
    of director (print)	 	Name
    of director (print)

 

[Signature
page to Forbearance and Fifth Amendment to

Amended
and Restated Loan and Security Agreement]

 

    	 

    	 

    

 

Schedule
1

 

ACKNOWLEDGMENT
OF AMENDMENT

AND REAFFIRMATION OF GUARANTY

 

Section
1. Guarantor hereby acknowledges and confirms that it has reviewed and approved the terms and conditions of the Forbearance
and Fifth Amendment to Amended and Restated Loan and Security Agreement dated as of even date herewith (“the “Amendment”).

 

Section
2. Guarantor hereby consents to the Amendment and agrees that the Guaranty relating to the Obligations of Borrower under the
Loan Agreement shall continue in full force and effect, shall be valid and enforceable and shall not be impaired or otherwise
affected by the execution of the Amendment or any other document or instruction delivered in connection herewith.

 

Section
3. Guarantor represents and warrants that, after giving effect to the Amendment, all representations and warranties contained
in the Guaranty are true, accurate and complete as if made the date hereof.

 

Dated
as of January 16, 2019

 

GUARANTOR:

 

	Executed
    by VIVOPHARM PTY LTD in accordance with Section 127 of the Corporations Act 2001	 	 
	 	 	 
	/s/
    John A. Roberts	 	/s/
    Ralf Brandt
	Signature
    of director	 	Signature
    of director
	 	 	 
	John
    A. Roberts	 	Ralf
    Brandt
	Name
    of director (print)	 	Name
    of director (print)FORBEARANCE
AGREEMENT

AND

MODIFICATION
NO. 4 TO LOAN AND SECURITY AGREEMENT

 

This
FORBEARANCE AGREEMENT AND MODIFICATION NO. 4 TO LOAN AND SECURITY AGREEMENT (this “Agreement”)
is made and entered into as of January 16, 2019, by and among PARTNERS FOR GROWTH IV, L.P., a Delaware limited partnership
(“PFG”), as lender, and each of (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”),
(ii) GENTRIS, LLC, a Delaware limited liability company (“Delaware Subsidiary”), (iii) VIVOPHARM,
LLC, a Delaware limited liability company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD,
a company incorporated under the laws of Australia (“Australian Borrower”, and together with Parent,
Delaware Subsidiary and Vivo, jointly and severally, individually and separately, “Borrower”).

 

RECITALS

 

A.
Borrower and PFG are parties to that certain Loan and Security Agreement, dated as of March 22, 2017 (as the same may be amended,
modified and supplemented and in effect from time to time, the “Loan Agreement”) and the other Loan
Documents.

 

B.
As of December 31, 2018, there is owing under the Loan Agreement the sum of: (i) a principal amount of $6,000,000 (not including,
to the extent applicable, any contingent obligations), plus (ii) fees in the amount of $75,000, plus (iii) any accrued
and unpaid interest, legal fees and costs and all other outstanding amounts and costs due under the Loan Documents. Such amount,
plus accruing interest and costs and accrued and accruing attorneys’ fees and costs are hereinafter referred to herein as
the “Existing Debt.”

 

C.
The following Events of Default have occurred and exist under the Loan Documents or with respect to certain of the events described
in clause (7) below are anticipated to occur (collectively, the “Specified Default”): (1) an Event of
Default occurred with respect to the Senior Loan Documents, which constitutes an Event of Default under Section 6.1(g) of the
Loan Agreement, (2) Borrower failed to consummate an investor subordinated debt or equity financing providing not less than $3,000,000
in cash proceeds on or before November 30, 2018 as required by Section 6(c) of the Waiver Under Loan and Security Agreement dated
on or about November 19, 2018 among PFG and Borrower (the “November 2018 Waiver”), which constitutes
an Event of Default under Section 6 of the November 2018 Waiver, (3) Borrower failed to deliver by November 30, 2018 a new financial
plan reflecting Borrower’s prospective pro forma finances for the 2019 calendar year as required by Section 6(e) of the
November 2018 Waiver, which constitutes an Event of Default under Section 6 of the November 2018 Waiver, (4) Borrower failed to
provide the items required pursuant to Sections 6(a), 6(b) and 6(c) of the Schedule to the Loan Agreement for the month of October
2018 within the time required therefor, which constitutes an Event of Default under Section 6.1(c) of the Loan Agreement, (5)
the “Specified Defaults” set forth in the November 2018 Waiver occurred, (6) Borrower failed to provide the items
due within 30 days after the end of November 2018 pursuant to Section 6 of the Schedule to the Loan Agreement (the “November
Reporting”), which constitutes an Event of Default under Section 6.1(c) of the Loan Agreement, and (7) Borrower failed or
is anticipated to fail to comply with (i) the Minimum Adjusted EBITDA covenant and the Minimum Liquidity covenant, each as set
forth in Section 5 of the Schedule for the testing months ended December 31, 2018, January 31, 2019, February 28, 2019, and March
31, 2019, and (ii) the Minimum Revenues covenant as set forth in Section 5 of the Schedule for the testing quarters ending December
31, 2018 and March 31, 2019.

 

    	1

    	 

    

 

D.
The Specified Default entitles PFG to immediately enforce all the remedies set forth in the Loan Agreement and the other Loan
Documents. Borrower has requested that PFG forbear from exercising its rights and remedies regarding the Specified Default, and
PFG is agreeable to Borrower’s request, subject to the terms and conditions hereof.

 

NOW,
THEREFORE, for good and valuable consideration, the parties agree as follows:

 

AGREEMENT

 

1.
Defined Terms. Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Loan
Agreement. The term “Obligations”, as used in the Loan Agreement, shall include without limitation all of Borrower’s
indebtedness, liabilities and obligations under this Agreement and all documents and agreements relating hereto, and this Agreement
and all documents and agreements relating hereto are “Loan Documents” for all purposes of the Loan Agreement and this
Agreement.

 

2.
Acknowledgements. Borrower acknowledges that: (i) the Specified Default has occurred and presently exists under the
Loan Documents, and the same is a material Event of Default, (ii) the Obligations (including the Existing Debt) are due and owing
from Borrower to PFG without any defense, offset or counterclaim of any kind; (iii) pursuant to the Loan Documents, PFG has a
valid, perfected first-priority (subject to Permitted Liens to the extent the Loan Agreement expressly allows them to be prior
to the security interest of PFG) security interest in all of the Borrower’s present and future Collateral; (iv) subject
to the forbearance agreement set forth in Section 3 below, PFG has the right to take immediate possession of, and foreclose upon,
all of the Collateral, pursuant to the Loan Documents and to exercise all other rights and remedies granted to it under the Loan
Documents and by law; (v) PFG is not obligated to make any additional Loans or other credit extensions to the Borrower, under
the Loan Agreement or otherwise, and (vi) PFG is not agreeing in any way to waive the Specified Default as a result of this Agreement
or the performance by the parties of their respective obligations hereunder.

 

3.
Forbearance; Forbearance Period.

 

(a)
Forbearance. Subject to the terms and conditions contained herein and subject to performance by Borrower of all of the
terms of this Agreement and the Loan Agreement and other Loan Documents after the date hereof, PFG shall forbear from exercising
any remedies that PFG has against Borrower as a result of the occurrence of the Specified Default, until the earlier of the following
dates (the “Forbearance Period”): (i) the Scheduled Expiration Date, (ii) the date on which Senior Lender’s
agreement to forbear from exercising its rights or remedies pursuant the Senior Lender Forbearance Agreement ends, or (iii) the
date any Additional Default shall occur. In agreeing to forbear from exercising its remedies, PFG is not waiving the Specified
Defaults or any rights or remedies in connection therewith, all of which are expressly reserved. Upon the expiration of the Forbearance
Period, PFG may, at its sole option and in its sole discretion, exercise any and all rights or remedies in connection with the
Specified Defaults, without further notice. This forbearance shall not be deemed a continuing waiver or forbearance with respect
to any Event of Default of a nature similar to the Specified Default that may have occurred before or may occur after the date
of this Agreement.

 

    	2

    	 

    

 

(b)
Additional Default. As used in this Agreement, “Additional Default” means any of the following
(but not including the Specified Defaults): (i) any default, Default or Event of Default under the Loan Agreement or any other
Loan Document (including, without limitation, any breach of any term or provision of this Agreement, and any default or Event
of Default which has occurred as of this date other than the Specified Defaults), or (ii) any breach of any representation or
warranty in this Agreement or any other Loan Document. Without limiting any other provision of this Agreement, PFG may, in its
sole and absolute discretion, waive an Additional Default, but only in a specific written waiver signed by PFG, and no such waiver
shall imply or constitute an agreement on the part of PFG to any other Additional Defaults, whether or not similar to the Additional
Default waived. Borrower agrees to give PFG immediate written notice of any Additional Default. The occurrence of an Additional
Default shall constitute an Event of Default under the Loan Agreement, without the necessity of any notice or the passage of any
time period.

 

(c)
Scheduled Expiration Date. As used in this Agreement, “Scheduled Expiration Date” means February
15, 2019; provided that if and only if the LOI/Term Sheet Conditions are fully and timely satisfied, thereafter “Scheduled
Expiration Date” shall mean February 28, 2019; provided further that if and only if the LOI/Term Sheet Conditions and the
Confirmation Conditions are both fully and timely satisfied, thereafter “Scheduled Expiration Date” shall mean April
15, 2019.

 

4.
Senior Lender Forbearance. Borrower covenants and agrees that, within two Business Days after the date hereof, (i)
Senior Lender shall agree in writing to forbear from exercising its rights and remedies under the Senior Loan Documents with respect
to defaults and events of defaults thereunder that exist as of the date of such agreement, pursuant to a forbearance agreement
between Senior Lender and Borrower acceptable to PFG in its sole discretion (the “Senior Lender Forbearance Agreement”)
and (ii) Borrower shall provide PFG with evidence thereof satisfactory to PFG in its sole discretion. Without limitation on what
constitutes an Event of Default under the existing terms of the Loan Agreement, the occurrence of an Event of Default under the
Senior Loan Documents with respect to which Senior Lender has not agreed to forbear pursuant to the Senior Lender Forbearance
Agreement shall constitute an immediate Event of Default under the Loan Agreement and Additional Default hereunder.

 

5.
Borrower Sale. Borrower hereby covenants and agrees that:

 

(a)
Receipt of LOI/Term Sheet; LOI/Term Sheet Conditions. After the date hereof and on or before February 15, 2019, Borrower
shall (i) receive either a signed letter of intent or signed bona fide term sheet (the “LOI/Term Sheet”)
for the sale of all or substantially all of Borrower’s equity securities or assets to buyers satisfactory to PFG in all
respects with an anticipated closing date of on or before April 15, 2019 (the “Borrower Sale”) and (ii)
provide PFG with a copy of the LOI/Term Sheet and such other evidence of the occurrence of the requirements of clause (i) above
as is satisfactory to PFG in its sole discretion (collectively, the “LOI/Term Sheet Conditions”).

 

    	3

    	 

    

 

(b)
Receipt of Confirmation; Confirmation Conditions. After February 15, 2019 and on or before February 28, 2019, Borrower
shall provide PFG with evidence satisfactory to PFG in its sole discretion that, after February 15, 2019, the buyers outlined
in the LOI/Term Sheet have provided written confirmation that such buyers and Borrower have agreed to proceed with the Borrower
Sale and that any due diligence required by such buyers in connection therewith has begun (collectively, the “Confirmation
Conditions”).

 

(c)
Closing. On or before April 15, 2019, the Borrower Sale shall close and Borrower shall provide PFG with such evidence thereof
as is satisfactory to PFG in its sole discretion.

 

6.
Amendment-Reporting Cash Flow Projections. The following clause (i) is hereby added to the end of Section 6 of the
Schedule to the Loan Agreement (for purposes of clarity, said clause (i) replaces the clause (i) of Section 6 that was added pursuant
to that certain Conditional Waiver & Modification No. 1 to Loan and Security Agreement dated as of May 14, 2018 among PFG,
Parent and Delaware Subsidiary and shall remain as long as any Obligations remain outstanding):

 

“(i)
commencing on the first Monday following the date of the Fourth Modification and continuing every Monday of each calendar week
thereafter, by 5:00 PM (Boston, Massachusetts time) of each such Monday, (y) weekly cash flow projections for at least the immediately
succeeding fourteen (14) week period (inclusive of the calendar week during which such projections are hereby required to be provided)
that includes all expenses and foreseeable expenses, and (z) for the prior week, an actual results variance report that compares
the projections that had been made for that week to the actual results for such week and sets forth any material (as determined
by PFG in its reasonable judgment) variance; all in form and substance acceptable to PFG in all respects (including without limitation
presentation in Excel spreadsheet format and explanations of any such material variances).”

 

7.
November Reporting. Borrower shall provide PFG with the November Reporting as soon as available but in any event no
later than on January 18, 2019.

 

8.
Amendment-Additional Definitions. The following definitions are hereby added to Section 7 of the Loan Agreement, in
the appropriate alphabetical order:

 

“’Fourth
Modification’ means that certain Forbearance Agreement and Modification No. 4 to Loan and Security Agreement dated on
or about January 16, 2019 among PFG and Borrower.”

 

9.
Fee. Borrower shall pay PFG a fee of $75,000 in connection with this Agreement, which fee is fully earned and nonrefundable
as of the date hereof but shall be due and payable by Borrower upon the earliest to occur of: (i) April 15, 2019, (ii) repayment
of the monetary Obligations, and (iii) the occurrence of any Additional Default.

 

    	4

    	 

    

 

10.
Consent and Reaffirmation. Concurrently herewith, Borrower shall cause VIVOPHARM PTY LTD to execute and deliver to
PFG the Consent and Reaffirmation attached hereto as Schedule 1.

 

11.
Ratification by Borrower of PFG’s First Priority Security Interest in Collateral. Borrower hereby confirms and
ratifies PFG’s first priority lien and security interest in and to all Collateral. Borrower shall execute such security
agreements, financing statements and other documents as PFG may from time to time reasonably request to carry out the terms of
this Agreement and the Loan Agreement. Borrower authorizes PFG to file such financing statements and amendments relating to the
Collateral. Such liens and security interests shall secure all of the obligations of Borrower under this Agreement and the Loan
Agreement.

 

12.
Receipt and Application of Payments. All payments hereunder and under the Loan Agreement may, at PFG’s option,
be applied to the Obligations in such order and manner as PFG shall determine in its sole and absolute discretion. Acceptance
by PFG of any payment in an amount less than the amount then due shall be deemed an acceptance on account only, and the failure
to pay the entire amount then due shall be and continue to be an Event of Default pursuant to this Agreement and the Loan Agreement.
To the extent that PFG receives any payment or benefit and such payment or benefit, or any part thereof, is required to be repaid
to a trustee, receiver, or any other party under any bankruptcy or insolvency statute or law, state or federal law, common law
or equitable cause, then to the extent of such payment or benefit, the Existing Debt, or any part thereof intended to be satisfied
shall be revived and continued in full force and effect as if such payment or benefit had not been made, shall accrue interest
at the highest rate applicable to any portion thereof, shall be secured by the Collateral and payable on demand.

 

13.
Costs and Expenses. Without limiting the provisions of the Loan Agreement, Borrower shall reimburse PFG for all of
the costs, fees and expenses (including without limitation reasonable attorneys’ fees) which PFG has incurred or hereafter
incurs in connection with the negotiation, drafting or enforcement of this Agreement, or otherwise in connection with this Agreement
or the other Loan Documents, whether or not there is any litigation between the parties hereto.

 

14.
Representations and Warranties. Borrower represents and warrants to PFG as follows:

 

(a)
No Event of Default or failure of condition has occurred or exists, or would exist with notice or lapse of time or both under
the Loan Agreement, other than the Specified Default.

 

(b)
The Forbearance Period granted pursuant to the terms of this Agreement is reasonable.

 

(c)
All representations and warranties of Borrower in this Agreement and the Loan Agreement (as amended by this Agreement) and other
Loan Documents are true and correct as of the date hereof, and shall survive the execution of this Agreement.

 

    	5

    	 

    

 

(d)
PFG has not at any time directed or participated in any aspect of the management of Borrower or the conduct of Borrower’s
business. Borrower has made all business decisions independently of PFG, and PFG has limited its actions to those of a lender
of money and as set forth in the Loan Agreement.

 

(e)
PFG is not obligated to renew or forbear to enforce any obligations of Borrower other than the specific limited forbearance set
forth in this Agreement.

 

15.
Rights and Remedies.

 

(a)
Upon the occurrence and during the continuance of an Additional Default, PFG may, at its election, without notice of its election
and without demand, do any one or more of the following, all of which are authorized by Borrower:

 

(i)
Without notice to Borrower, set off and apply to the amounts due and owing under the Loan Agreement and this Agreement:

 

	 	(A)	any
    and all cash or certificates of deposit held by PFG for whatever purpose; and
	 	 	 
	 	(B)	indebtedness
    at any time owing to or for the credit or the account of Borrower held by PFG.

 

(ii)
Take action against Borrower for payment under the Loan Agreement and this Agreement;

 

(iii)
Exercise any right and remedy under the Loan Agreement and/or this Agreement and/or any other Loan Document and/or applicable
law.

 

(b)
PFG’s rights and remedies under this Agreement, the Loan Agreement and all other Loan Documents and under applicable law
shall be cumulative. PFG shall have all other rights and remedies not inconsistent herewith as provided under the Code, by law,
or in equity. No exercise by PFG of one right or remedy shall be deemed an election, and no waiver by PFG of any Event of Default
on the part of any Borrower shall be deemed a continuing waiver. No delay by PFG shall constitute a waiver, election, or acquiescence
by it. PFG shall have the right to take any action it deems necessary against any Borrower in order to enforce or perfect, or
to realize on its security interest in any collateral provided by such Borrower.

 

(c)
Upon the expiration of the Forbearance Period PFG may exercise any right and remedy under the Loan Agreement and/or this Agreement
and/or any other Loan Document and/or applicable law.

 

16.
Power of Attorney. Without limiting PFG’s other rights and remedies, PFG shall have the rights set forth in Section
6.4 of the Loan Agreement upon the occurrence and during the continuance of any Event of Default (unless otherwise provided for
in Section 6.4 of the Loan Agreement).

 

    	6

    	 

    

 

17.
Waivers of Notice and Cure. Borrower acknowledges that Events of Default have occurred under the Loan Agreement that,
but for this Agreement, would have entitled PFG to exercise all the remedies available to PFG under the Loan Agreement and applicable
law. Borrower waives all notices of default and rights to cure that are otherwise provided in the Loan Agreement, any Loan Documents
or applicable law. Borrower further waives any claim that a sale or other disposition by PFG of the Collateral is not commercially
reasonable because PFG disclaims any warranties with respect to such sale or other disposition, including, without limitation,
disclaimers of warranties relating to title, possession, quiet enjoyment, or the like.

 

18.
Release.

 

(a)
Borrower acknowledges that PFG would not enter into this Agreement without Borrower’s assurance hereunder. Except for the
obligations arising hereafter under this Agreement and obligations arising hereafter under the Loan Agreement, Borrower hereby
absolutely discharges and releases PFG, any person or entity that has obtained any interest from PFG under the Loan Agreement
and each of PFG’s and such entity’s former and present partners, stockholders, officers, directors, employees, successors,
assignees, agents and attorneys from any known or unknown claims which the Borrower now has against PFG of any nature, including
any claims that Borrower, its successors, counsel, and advisors may in the future discover they would have now had if they had
known facts not now known to them, whether founded in contract, in tort or pursuant to any other theory of liability, including
but not limited to any claims arising out of or related to the Loan Agreement or the transactions contemplated thereby.

 

(b)
The provisions, waivers and releases set forth in this section are binding upon Borrower and Borrower’s shareholders, agents,
employees, assigns and successors in interest, and each and every party claiming rights by or through Borrower. The provisions,
waivers and releases of this section shall inure to the benefit of PFG and its agents, employees, officers, directors, assigns
and successors in interest.

 

(c)
Borrower warrants and represents that Borrower is the sole and lawful owner of all right, title and interest in and to all of
the claims released hereby and Borrower has not heretofore voluntarily, by operation of law or otherwise, assigned or transferred
or purported to assign or transfer to any person any such claim or any portion thereof. Borrower shall indemnify and hold harmless
PFG from and against any claim, demand, damage, debt, liability (including payment of attorneys’ fees and costs actually
incurred whether or not litigation is commenced) based on or arising out of any assignment or transfer.

 

(d)
The provisions of this section shall survive payment in full of the Obligations, full performance of all the terms of this Agreement
and the Loan Agreement, and/or PFG’s actions to exercise any remedy available under the Loan Agreement or otherwise.

 

19.
Consultation of Counsel. Borrower acknowledges that Borrower has had the opportunity to be represented by legal counsel
of its own choice throughout all of the negotiations that preceded the execution of this Agreement. Borrower has executed this
Agreement after reviewing and understanding each provision of this Agreement and without reliance upon any promise or representation
of any person or persons acting for or on behalf of PFG. Borrower further acknowledges that Borrower and its counsel have had
adequate opportunity to make whatever investigation or inquiry they may deem necessary or desirable in connection with the subject
matter of this Agreement prior to the execution hereof and the delivery and acceptance of the consideration described herein.

 

    	7

    	 

    

 

20.
Miscellaneous.

 

(a)
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of Borrower and PFG and their
respective successors and assigns; provided, however, that the foregoing shall not authorize any assignment by Borrower of its
rights or duties hereunder.

 

(b)
Integration. This Agreement and any documents executed in connection herewith or pursuant hereto contain the entire agreement
between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, offers and negotiations,
oral or written, with respect thereto and no extrinsic evidence whatsoever may be introduced in any judicial or arbitration proceeding,
if any, involving this Agreement; except that any financing statements or other agreements or instruments filed by PFG with respect
to Borrower shall remain in full force and effect.

 

(c)
Recitals. The recitals in this Agreement are confirmed by the parties as true and correct and are incorporated herein by
reference. The recitals are a substantive, contractual part of this Agreement.

 

(d)
Course of Dealing; Waivers. No course of dealing on the part of PFG or its officers, nor any failure or delay in the exercise
of any right by PFG, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude
any later exercise of any such right. PFG’s failure at any time to require strict performance by Borrower of any provision
shall not affect any right of PFG thereafter to demand strict compliance and performance. Any suspension or waiver of a right
must be in writing signed by an officer of PFG.

 

(e)
Time is of the Essence. Time is of the essence as to each and every term and provision of this Agreement and the other
Loan Agreement.

 

(f)
Construction; Survival. The terms and conditions set forth in this Agreement are the product of joint draftsmanship by
all parties, each having had the opportunity to be represented by counsel and any ambiguities in this Agreement or any documentation
prepared pursuant to or in connection with this Agreement shall not be construed against any of the parties because of draftsmanship.
The warranties and representations of the parties in this Agreement shall survive the termination of this Agreement.

 

(g)
Effectiveness of Loan Agreement. Except as explicitly set forth herein, the Loan Agreement remains unmodified and in full
force and effect.

 

(h)
Further Assurances. Borrower shall execute such security agreements and other documents and agreements, and take such actions,
as PFG may from time to time specify to carry out the terms of this Agreement and the Loan Agreement and other Loan Documents.
Borrower authorizes PFG to file all such financing statements and amendments relating to the Collateral as PFG shall determine
are necessary or convenient to carry out the terms of this Agreement and the Loan Agreement and other Loan Documents. All liens
and security interests in favor of PFG shall secure all of the Obligations, including without limitation the obligations of Borrower
under this Agreement and the Loan Agreement.

 

    	8

    	 

    

 

(i)
Counterparts. This Agreement may be executed by one or more of the parties to this Agreement in any number of separate
counterparts, each of which, when so executed, shall be deemed an original, and all of said counterparts taken together shall
be deemed to constitute but one and the same instrument.

 

(j)
Entire Agreement. This Agreement, together with the other Loan Documents, sets forth the entire agreement and understanding
among Borrower and PFG and supersedes all prior or contemporaneous agreements and understandings of such Persons, verbal or written,
relating to the subject matter hereof and thereof.

 

(k)
No Third Parties Benefited. This Agreement is made and entered into for the sole protection and legal benefit of Borrower,
PFG, and their respective permitted successors and assigns, and no other Person shall be a direct or indirect legal beneficiary
of, or have any direct or indirect cause of action or claim in connection with, this Agreement or any of the other Loan Documents.

 

(l)
Assignment and Indemnity. Borrower consents to PFG’s assignment of all or any part of PFG’s rights under this
Agreement and the Loan Agreement. Borrower shall indemnify and defend and hold PFG and any assignee of PFG’s interests harmless
from any actions, costs, losses or expenses (including attorneys’ fees) arising out of such assignment, this Agreement or
the Loan Agreement.

 

(m)
Governing Law; Jurisdiction; Venue; Mutual Waiver of Jury Trial. Sections 8.20 (titled: “Governing Law; Jurisdiction;
Venue”) and 8.2r (titled: “Mutual Waiver of Jury Trial”) of the Loan Agreement shall apply to this Agreement
and are be incorporated herein by this reference.

 

[Remainder
of page intentionally left blank; signature pages follow.]

 

    	9

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the
date first set forth above.

 

	Borrower:	 	PFG:
	 	 	 	 	 
	CANCER
    GENETICS, INC.	 	

PARTNERS
FOR GROWTH IV, L.P.

	 	 	 	 	 
	By	/s/
    John A. Roberts	 	By 	/s/
    Philip Lawson
	Name	John
    A. Roberts	 	Name	Philip
    Lawson
	Title	Chief
    Executive Officer	 	Title:	Manager,
    Partners for Growth IV, LLC
	 	 	 		Its
    General Partner

 

	Borrower:	 	Borrower:
	 	 	 	 	 
	GENTRIS,
    LLC	 	VIVOPHARM,
    LLC
	 	 	 
	By	/s/
    John A. Roberts	 	By	/s/
    John A. Roberts
	Name	John
    A. Roberts	 	Name	John
    A. Roberts
	Title	Chief
    Executive Officer	 	Title	Chief
    Executive Officer

 

	Borrower:	 
	 	 
	Executed
    by RDDT A VIVOPHARM COMPANY PTY LTD in accordance with Section 127 of the Corporations Act 2001	 
	 	 
	/s/
    John A. Roberts	 
	Signature
    of director	 

 

	Name	John
    A. Roberts	 

 

	/s/
    Ralf Brandt	 
	Signature of director	 

 

	Name
                                         
	

Ralf Brandt	 

 

    	10

    	 

    

 

Schedule
1

 

CONSENT
AND REAFFIRMATION

 

Section
1. The undersigned acknowledges and confirms that it has reviewed and approved the terms and conditions of the Forbearance
Agreement and Modification No. 4 to Loan and Security Agreement dated on or about the date hereof (the “Agreement”).

 

Section
2. The undersigned consents to the Agreement and agrees that the guarantee, security deed and other agreements and documents
(the “Documents”) provided by the undersigned relating to the Obligations of Borrower under the Loan and Security
Agreement shall continue in full force and effect, shall be valid and enforceable and shall not be impaired or otherwise affected
by the execution of the Agreement or any other document or instruction delivered in connection herewith.

 

Section
3. The undersigned represents and warrants that, after giving effect to the Amendment, all representations and warranties
contained in the Documents are true, accurate and complete as if made the date hereof.

 

Dated
as of January 16, 2019

 

	Executed
    by VIVOPHARM PTY LTD in accordance with Section 127 of the Corporations Act 2001	 	 
	 	 	 
	/s/
    John A. Roberts	 	/s/
    Ralf Brandt
	Signature
    of director	 	Signature
                                         of director

         

	John
    A. Roberts	 	Ralf
    Brandt
	Name
    of director (print)	 	Name
    of director (print)

 

Signature
Page to Schedule to Loan and Security Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]